3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
Vincristine
9
Cyclophosphamide
8
Magnetic Resonance Spectroscopy
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Irinotecan
6
Biopsy
5
Radiotherapy
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Dactinomycin
4
fludarabine
3
Vinorelbine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
ensartinib
2
Proton Therapy
2
LY3023414
2
Ifosfamide
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Dexrazoxane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.